An optical pooled screening method can correlate phenotypes and perturbations in any nucleated cell type.

Pooled genetic CRISPR screening is improved in complex models through leveraging internal controls.

A protein platform rapidly develops peptide-focused major histocompatibility complex class I binders with high specificity.

Specific binders to peptide–MHC class II are rapidly generated without laborious screening.

Generative artificial intelligence is used to design an effective treatment for inflammatory bowel disease in preclinical models.

CAR-T and NK cells engineered using a non-viral circular single-stranded DNA system show effective anti-tumor function.

To enhance the safety and security of the US bioeconomy, a new public–private partnership should be established to facilitate information sharing and threat analysis among industry, government and academia, and to develop and deploy safeguards.

After two decades of experience with biosimilars, physicochemical and in vitro biological comparison with their reference products appear sufficient to guarantee clinical safety and efficacy. Hence, the regulation of biosimilars has become redundant, and biopharmaceuticals should now be regulated through the generic pathway available for small molecules.

Merger and acquisition activity is at a seven-year low in 2024 as buyers digest prior deals and US election jitters delayed further spending. Expect a pick-up in 2025.